Ligand Pharmaceuticals Inc. Awarded U.S. Patent for LGD-4665

SAN DIEGO--(BUSINESS WIRE)--Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) (the Company or Ligand) today announced that the United States Patent and Trademark Office issued U.S. Patent No. 7,314,887, titled “Thrombopoietin Activity Modulating Compounds and Methods,” to Ligand for LGD-4665, the Company’s lead thrombopoietin (TPO) receptor agonist and a family of related compounds. The patent describes LGD-4665 and other small-molecule TPO mimetic compounds discovered at Ligand, formulations involving these compounds, as well as methods of making and using the compounds and formulations.

Back to news